subarachnoid hemorrhage
Conditions
Interventions
Test group:Dexamethasone plus standard care.
Control group:Standard Treatment
Sponsors
The Eighth Affilliated Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age 18 years or older; 2. Diagnosis of aneurysmal subarachnoid hemorrhage (SAH) confirmed by cranial CT; 3. Time from onset to randomization within 48 hours; 4. Subject or their legally authorized representative has signed a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with obvious irreversible brainstem or thalamic injury; 2. Pregnant or breastfeeding women, or women planning pregnancy within one year; 3. Any terminal-stage disease with an expected survival < 12 months; 4. Allergy to glucocorticoids; 5. Patients with Alzheimer’s disease or psychiatric disorders who cannot complete follow-up as required; 6. Presence of any serious comorbid disease that, in the investigator’s judgment, may interfere with trial outcomes, including diseases of the respiratory, cardiovascular, digestive, genitourinary, endocrine, immune, or hematologic systems; 7. History of bleeding within the past month (gastrointestinal or urinary tract bleeding); 8. Systemic infectious disease; 9. Glaucoma or macular edema; 10. Currently participating in other clinical trials; 11. Patient or their legal guardian unwilling to sign a written informed consent form; 12. Any condition that could endanger the patient or affect participation in the study after initiation of the study treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 180-day favorable outcome rate (mRS 0-3 score (%));180-day mortality rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| mRS score at 180 days (mRS shift);180-day Favorable Outcome Rate (mRS 0-2, %);180-day excellent outcome rate (mRS 0–1 score (%)).;Incidence of delayed cerebral ischemia (DCI);Incidence of symptomatic cerebral vasospasm;180-day EuroQol five-dimensional questionnaire (EQ-5D);360-day favorable outcome rate (mRS 0-3 score (%));360-day mortality rate;mRS score at 360 days (mRS shift);360-day Favorable Outcome Rate (mRS 0-2, %);360-day excellent outcome rate (mRS 0–1 score (%)).; | — |
Countries
China
Contacts
Public ContactLuo Bin
Department of Neurosurgery, the Eighth Affiliated Hospital of Sun Yat-Sen University
Outcome results
None listed